A review of its characteristics and therapeutic use in cardiac ischemya and in primary and secondary deficits of carnitine, associated to fatty acid metabolism
The future of healthcare is predictive, personalized, and proactive
But because the landscape around compounded GLP-1 medications has shifted dramatically since the FDA resolved the semaglutide shortage in February 2025, and what was once a straightforward decision now involves regulatory gray areas, legal battles, and quality control questions that most people never expected to navigate
According to Leverage, a research platform funded by the Robert Wood Johnson Foundation, at least 15 states included anti-obesity drugs in their employee health plans in 2025, while nearly half the states limited coverage of GLP-1s
It is because many off-patent medicines are sold under different brand names
Its mainly beneficial for patients who cant tolerate newer GLP-1 variants